KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Return on Sales (2017 - 2025)

Amneal Pharmaceuticals has reported Return on Sales over the past 9 years, most recently at 0.06% for Q4 2025.

  • Quarterly results put Return on Sales at 0.06% for Q4 2025, up 9.0% from a year ago — trailing twelve months through Dec 2025 was 0.04% (up 7.0% YoY), and the annual figure for FY2025 was 0.04%, up 7.0%.
  • Return on Sales for Q4 2025 was 0.06% at Amneal Pharmaceuticals, up from 0.02% in the prior quarter.
  • Over the last five years, Return on Sales for AMRX hit a ceiling of 0.06% in Q4 2025 and a floor of 0.43% in Q2 2022.
  • Median Return on Sales over the past 5 years was 0.01% (2024), compared with a mean of 0.02%.
  • Biggest five-year swings in Return on Sales: plummeted -49bps in 2022 and later skyrocketed 48bps in 2023.
  • Amneal Pharmaceuticals' Return on Sales stood at 0.04% in 2021, then soared by 75bps to 0.01% in 2022, then plummeted by -1465bps to 0.15% in 2023, then soared by 81bps to 0.03% in 2024, then surged by 314bps to 0.06% in 2025.
  • The last three reported values for Return on Sales were 0.06% (Q4 2025), 0.02% (Q3 2025), and 0.05% (Q2 2025) per Business Quant data.